Houston company focused on renewables sees high growth potential amid 'energy revolution'

seeing green

According to Houston-based ENGlobal, the company "has more promising opportunities for significant new business than at any time in [the] company's history." Photo via Getty Images

For Houston-based ENGlobal Corp., a provider of engineering and automation services geared toward the energy industry, renewable fuel facilities are a business pipeline gushing with opportunity.

ENGlobal's potential contracts for renewable fuels projects currently exceed $320 million, says Bill Coskey, the company's founder, president, and CEO. That's about six times the amount of ENGlobal's revenue through the first nine months of this year — $52.9 million.

During the company's third-quarter earnings call November 5, Coskey said publicly traded ENGlobal "has more promising opportunities for significant new business than at any time in our company's history."

Many of those opportunities stem from ENGlobal's shift a couple of years ago to a sharp focus on the renewable energy sector. This includes building utility-scale systems to store wind and solar power, and supplying modular engineered process plants for forms of energy like hydrogen and renewable diesel. Modular process plants consist of separately engineered and automated modules that are made off-site and assembled on-site.

"Manufacturing plants based on modular equipment are emerging as a viable and beneficial alternative to conventional stick-built processing plants. Modular equipment offers several benefits, including flexibility in plant siting, fewer safety concerns during construction, and ease of equipment modification," according to the American Institute of Chemical Engineers.

ENGlobal is engineering and fabricating a modular hydrogen plant for a renewal diesel facility scheduled for completion in May. Incorporating proprietary technology from Denmark-based Haldor Topsoe (which has two offices and one plant in the Houston area), this hydrogen plant will consume about 20 percent less feed and fuel than conventional hydrogen plants, leading to lower operating costs and a smaller carbon footprint. It's the first facility of its kind in the U.S. This $25 million project falls into a bucket of modular process plants — valued at $10 million to $200 million each — that ENGlobal typically pursues.

ENGlobal's emphasis on renewable energy is paying off, especially now. That's because this sector is less susceptible to economic harm caused by the coronavirus pandemic and to the downturn in the oil and gas industry, according to Coskey.

"To the contrary, the green and renewable energy sector is driven by a different set of project economics — the majority of which play directly to our core strengths and capabilities," Coskey said during the November 5 earnings call.

ENGlobal comprises two business units that are capitalizing on those core strengths and capabilities:

  • Engineering, procurement, and construction management
  • Automation

Through September 26, the automation segment of the business accounted for 63 percent of the company's revenue this year, with engineering, procurement, and construction at 37 percent. In the third quarter, the balance was roughly 50-50.

For the nine-month period ended September 26, ENGlobal posted a 33 percent increase in revenue compared with the same period a year earlier. Revenue for the period rose 37 percent in the automation segment of the business and 27 percent in the engineering, procurement, and construction management segment.

Looking ahead, Coskey says plants like the one employing the Haldor Topsoe technology are "a big area of growth for us."

"We've built a business which is really vertically integrated. We can engineer and design, we can mechanically fabricate the processing modules, we can automate them, we can go onto the site and start them up. So we have full-service capabilities," Coskey says in an interview.

Those capabilities are helping ENGlobal, which Coskey started in 1985, capitalize on what he dubs the "energy revolution" in the U.S.

"Oil and gas has a long runway and is sometimes not given enough credit," he says. "But I can tell you that the capital spending for traditional oil and gas projects pretty much dried up during the course of this year. And we had to look for other sources of work for our people, so we were fortunate to have these renewable energy projects to work on."

Evercore ESI predicts capital spending on energy exploration and production in the U.S. will fall 43 percent this year compared with 2019. Meanwhile, S&P Global Market Intelligence forecasts $14.26 billion in capital spending this year on renewable energy by major U.S. utilities, up more than 20 percent from an earlier projection for 2020. The share of U.S. electricity generation from renewable energy is expected to increase from 18 percent in 2019 to 20 percent this year and 21 percent in 2021, the U.S. Energy Information Administration says.

"There's a lot of money that used to flow into oil and gas projects that now seems to be flowing into renewable energy projects," Coskey says. "We were lucky to identify that early and be positioned to capture some of that."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings